v3.26.1
Consolidated Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2024
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Revenue           $ 7,806,000
Operating Expenses:              
Research and development $ 2,000 $ 14,000   $ 5,000 $ 33,000 38,000 7,166,000
General and administrative 1,044,000 1,534,000   2,333,000 3,362,000 5,131,000 7,785,000
Loss on MannKind Transaction           2,618,000
Total operating expenses 1,046,000 1,548,000   2,338,000 3,395,000 5,169,000 17,569,000
Loss from operations (1,046,000) (1,548,000)   (2,338,000) (3,395,000) (5,169,000) (9,763,000)
Other income (expense):              
Interest income 10,000 41,000   22,000 94,000 144,000 467,000
Fair value adjustment of warrants 1,000   67,000 67,000 (67,000)
Other income (expense), net (43,000)   108,000 (123,000) (204,000) (196,000)
Total other income (expense), net 10,000 (1,000)   130,000 38,000 7,000 204,000
Income tax provision (benefit)            
Net loss (1,036,000) (1,549,000)   (2,208,000) (3,357,000) $ (5,162,000) [1] $ (9,559,000) [1]
Dividends accrued on Series B Convertible Preferred Stock (16,000)   (16,000)    
Net loss attributable to common stockholders $ (1,052,000) $ (1,549,000)   $ (2,224,000) $ (3,357,000)    
Net loss per share - basic $ (0.29) $ (0.42)   $ (0.61) $ (0.92) $ (1.41) $ (2.62)
Net loss per share - diluted $ (0.29) $ (0.42)   $ (0.61) $ (0.92) $ (1.41) $ (2.62)
Weighted-average common shares outstanding - basic 3,652,285 3,652,285   3,652,285 3,652,285 3,652,285 3,652,285
Weighted-average common shares outstanding - diluted 3,652,285 3,652,285   3,652,285 3,652,285 3,652,285 3,652,285
Eos SENOLYTIXS Inc [Member]              
Revenue  
Operating Expenses:              
Research and development 1,138,522 3,375 8,970 1,587,705 26,600 35,225  
General and administrative 329,135 54,086 67,925 462,384 109,622 217,795  
Total operating expenses 1,467,657 57,461 76,895 2,050,089 136,222 253,020  
Other income (expense):              
Fair value adjustment of warrants       4,000    
Promissory note financing expense 847,375   847,375    
Issuance costs related to the Series A offering securities 80,464   80,464    
Loss on issuance of Series A Preferred Stock offering 556,000   556,000    
Change in fair value of preferred stock forward liability (4,000)   (4,000)    
Interest expense 49,793   49,793    
Net loss before income tax provision (benefit) 2,997,289 57,461 76,895 3,579,721 136,222 253,020  
Income tax provision (benefit)  
Net loss $ (2,997,289) $ (57,461) $ (76,895) $ (3,579,721) $ (136,222) $ (253,020)  
Net loss per share - basic $ (0.60) $ (0.01) $ (0.07) $ (0.72) $ (0.03) $ (0.05)  
Net loss per share - diluted $ (0.60) $ (0.01) $ (0.07) $ (0.72) $ (0.03) $ (0.05)  
Weighted-average common shares outstanding - basic 5,000,000 5,000,000 1,068,493 5,000,000 5,000,000 5,000,000  
Weighted-average common shares outstanding - diluted 5,000,000 5,000,000 1,068,493 5,000,000 5,000,000 5,000,000  
[1] The dollar amounts reported represent the amount of net loss, in thousands, reflected in Pulmatrix’s consolidated audited financial statements for each applicable year.